Gut Health
Overview
Peptide therapy for gut health encompasses inflammatory bowel disease (IBD), gastric and duodenal ulcers, leaky gut syndrome (intestinal hyperpermeability), and dysbiosis-related conditions. Oral administration delivers peptides directly to the gut lumen for local action. BPC-157 in particular has an exceptional safety record and decades of research supporting its gastroprotective effects.
Recommended Peptides
- BPC-157 – oral administration preferred; heals gastric mucosa, reverses NSAID damage, reduces gut inflammation, and restores intestinal barrier integrity; effective for IBD, ulcers, and leaky gut
- KPV – anti-inflammatory tripeptide derived from alpha-MSH; reduces gut inflammation and colitis; can be taken orally for local gut action
- VIP – vasoactive intestinal peptide; modulates gut motility, reduces intestinal inflammation, and supports mucosal immunity; relevant for IBD and IBS
Protocols
Related Conditions
Research Summary
The strongest evidence for peptide therapy in gut health comes from BPC-157's extensive preclinical record. Sikiric et al. (2013) comprehensively reviewed BPC-157 as an "antidote" against NSAID-induced GI toxicity (PMID-22950504). Park et al. (2020) demonstrated BPC 157 stabilizes intestinal permeability and enhances tight junction integrity against NSAID damage (PMID-32445447). All GI evidence for BPC-157 remains preclinical; no human GI trials have been published.
Related
#condition #gastrointestinal